Basket Trials and the MD Anderson Precision Medicine Clinical Trials Platform.


Journal

Cancer journal (Sudbury, Mass.)
ISSN: 1540-336X
Titre abrégé: Cancer J
Pays: United States
ID NLM: 100931981

Informations de publication

Date de publication:
Historique:
entrez: 24 7 2019
pubmed: 25 7 2019
medline: 28 7 2020
Statut: ppublish

Résumé

Precision medicine incorporates information regarding tumor biology involved in patients' carcinogenesis and individualized treatment of patients using drugs that inhibit the molecular basis of their disease. Implementation of precision medicine accelerated the drug approval process, translating discoveries in basic science and biotechnology into patient care. Clinical trials with innovative or adaptive design including "basket" and "umbrella" trials explore personalized therapies against in selected tumor types and/or across tumor types. In 2007, we started the Initiative for Molecular Profiling and Advanced Cancer Therapy, the first precision medicine program across tumor types. We demonstrated that therapy matched to patients' tumor molecular profiling is associated with improved rates of response, progression-free survival, and overall survival compared with nonmatched targeted therapy. We have now entered a new era of precision medicine that includes comprehensive tumor testing and multiple innovative modalities hoping to overcome the complexity of tumor biology to improve patient outcomes.

Identifiants

pubmed: 31335392
doi: 10.1097/PPO.0000000000000393
pii: 00130404-201907000-00009
pmc: PMC6657521
mid: NIHMS1532215
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

282-286

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States

Références

J Clin Oncol. 2008 Aug 20;26(24):3913-5
pubmed: 18711176
N Engl J Med. 2010 Aug 26;363(9):809-19
pubmed: 20818844
Clin Cancer Res. 2012 Nov 15;18(22):6373-83
pubmed: 22966018
N Engl J Med. 2012 Nov;367(18):1694-703
pubmed: 23020132
Oncotarget. 2013 May;4(5):705-14
pubmed: 23670029
Cell Rep. 2014 Jan 30;6(2):377-87
pubmed: 24440717
Clin Cancer Res. 2014 Sep 15;20(18):4827-36
pubmed: 24987059
Cancer Res. 2015 Apr 1;75(7):1187-90
pubmed: 25672981
Clin Cancer Res. 2015 May 15;21(10):2213-20
pubmed: 25979927
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Lancet Oncol. 2015 Oct;16(13):1324-34
pubmed: 26342236
Mol Cancer Ther. 2016 Oct;15(10):2475-2485
pubmed: 27466356
J Clin Oncol. 2017 Jan 20;35(3):271-273
pubmed: 27893325
N Engl J Med. 2017 Jul 6;377(1):62-70
pubmed: 28679092
JCO Precis Oncol. 2017;2017:null
pubmed: 29082359
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758
pubmed: 30787022
Nat Med. 2019 May;25(5):751-758
pubmed: 31011205
J Clin Oncol. 1983 Nov;1(11):710-9
pubmed: 6668489

Auteurs

Rabih Said (R)

From the Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH